<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">75607</article-id><article-id pub-id-type="doi">10.7554/eLife.75607</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Amoxicillin-resistant <italic>Streptococcus pneumoniae</italic> can be resensitized by targeting the mevalonate pathway as indicated by sCRilecs-seq</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-266161"><name><surname>Dewachter</surname><given-names>Liselot</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1080-1656</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284248"><name><surname>Dénéréaz</surname><given-names>Julien</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-266162"><name><surname>Liu</surname><given-names>Xue</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6485-1865</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-266164"><name><surname>de Bakker</surname><given-names>Vincent</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1019-3558</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-266165"><name><surname>Costa</surname><given-names>Charlotte</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-266166"><name><surname>Baldry</surname><given-names>Mara</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-266167"><name><surname>Sirard</surname><given-names>Jean-Claude</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-76667"><name><surname>Veening</surname><given-names>Jan-Willem</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3162-6634</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Fundamental Microbiology</institution>, <institution>University of Lausanne</institution>, <addr-line><named-content content-type="city">Lausanne</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff2"><institution content-type="dept">Department of Pharmacology</institution>, <institution>Shenzhen University Health Science Center</institution>, <addr-line><named-content content-type="city">Shenzhen</named-content></addr-line>, <country>China</country></aff><aff id="aff3"><institution>University of Lille</institution>, <addr-line><named-content content-type="city">Lille</named-content></addr-line>, <country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-119090"><name><surname>Winkler</surname><given-names>Malcolm</given-names></name><role>Reviewing editor</role><aff/></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>Jan-Willem.Veening@unil.ch</email> (JV);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>24</day><month>06</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e75607</elocation-id><history><date date-type="received"><day>16</day><month>11</month><year>2021</year></date><date date-type="accepted"><day>23</day><month>06</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Dewachter et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Dewachter et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-75607-v1.pdf"/><abstract><p>Antibiotic resistance in the important opportunistic human pathogen <italic>Streptococcus pneumoniae</italic> is on the rise. This is particularly problematic in the case of the β-lactam antibiotic amoxicillin, which is the first-line therapy. It is therefore crucial to uncover targets that would kill or resensitize amoxicillin-resistant pneumococci. To do so, we developed a genome-wide, single-cell based, gene silencing screen using CRISPR interference called sCRilecs-seq (subsets of CRISPR interference libraries extracted by fluorescence activated cell sorting coupled to next generation sequencing). Since amoxicillin affects growth and division, sCRilecs-seq was used to identify targets that are responsible for maintaining proper cell size. Our screen revealed that downregulation of the mevalonate pathway leads to extensive cell elongation. Further investigation into this phenotype indicates that it is caused by a reduced availability of cell wall precursors at the site of cell wall synthesis due to a limitation in the production of undecaprenyl phosphate (Und-P), the lipid carrier that is responsible for transporting these precursors across the cell membrane. The data suggest that, whereas peptidoglycan synthesis continues even with reduced Und-P levels, cell constriction is specifically halted. We successfully exploited this knowledge to create a combination treatment strategy where the FDA-approved drug clomiphene, an inhibitor of Und-P synthesis, is paired up with amoxicillin. Our results show that clomiphene potentiates the antimicrobial activity of amoxicillin and that combination therapy resensitizes amoxicillin-resistant <italic>S. pneumoniae</italic>. These findings could provide a starting point to develop a solution for the increasing amount of hard-to-treat amoxicillin-resistant pneumococcal infections.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000780</institution-id><institution>European Commission</institution></institution-wrap></funding-source><award-id>Marie Sk&amp;#x0142;odowska Curie 837923</award-id><principal-award-recipient><name><surname>Dewachter</surname><given-names>Liselot</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>771534-PneumoCaTChER</award-id><principal-award-recipient><name><surname>Veening</surname><given-names>Jan-Willem</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>310030_200792,310030_192517,40AR40_185533,51NF40_180541</award-id><principal-award-recipient><name><surname>Veening</surname><given-names>Jan-Willem</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100018693</institution-id><institution>HORIZON EUROPE Framework Programme</institution></institution-wrap></funding-source><award-id>847786</award-id><principal-award-recipient><name><surname>Sirard</surname><given-names>Jean-Claude</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All experiments complied with national, institutional and European regulations and ethical guidelines, were approved by our Institutional Animal Care and Use guidelines (D59-350009, Institut Pasteur de Lille; Protocol APAFIS#16966 201805311410769_v3) and were conducted by qualified, accredited personnel.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Sequencing data is available at SRA under accession number PRJNA763896. Much of this work is based upon microscopy and snap shots and movies of most experiments are included in the manuscript and supporting files. Raw microscopy images are available at the BioImage Archive (accession number S-BIAD477).</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Veening J-W</collab><collab>et al</collab></person-group><year iso-8601-date="2021">2021</year><source>Amoxicillin-resistant Streptococcus pneumoniae can be resensitized by targeting the mevalonate pathway as identified by sCRilecs-seq</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA763896">https://www.ncbi.nlm.nih.gov/bioproject/PRJNA763896</ext-link><comment>NCBI SRA, PRJNA763896</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-75607-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>